Financial update. A financial update to be provided by the Borrower to KPMG no later than 15 September 2021 consisting of (i) the Borrower’s Interim Accounts (S1) (including the Borrower’s semi-annual balance sheet), (ii) an impact analysis of published and final “methode besluit” on financial projections, (iii) a trading update of Capex and (iv) an overview of other events or developments which may have a significant impact on the net debt position or financial forecast of the Borrower.
Financial update. Xxxxx Xxxxxx, Principal Administrative Analyst for DPW, provided a follow-up on the Financial Report presented at the July 19, 2023 meeting as requested by the GFDC. The report covered the following items: • FY 2022-23 Budget and Actual Expenditures • FY 2022-23 Budget and Actual Revenue • FY 2022-23 Lease Revenue by Category • FY 2017-18 through FY 2025-26 Airports Lease Revenue Totals • AEF Balance After the presentation, there was discussion regarding Fuel Flowage Fees. Xx. Xxxxxx stated that there was going to be a review of Rates and Charges soon. Council requested that the topic of Fuel Flowage Fees be put on the agenda for the following meeting. Council requested that a follow-up on the depreciation balance be provided at the next meeting.
Financial update. (Referring as necessary to Board Papers, other documents as appendices)
Financial update. Xx. Xxxxx informed the council that DPW Financial Services requested to postpone the Financial Update until the November meeting. At that time, the CAFR should be complete, which will include official end of year numbers to ensure the most accurate reporting. The requested items will remain on the agenda and be provided at the next meeting: • Budget vs Annual • Breakdown of Revenue from Industrial Leases and Aviation Leases • Corrected numbers for FY 25-26 Lease Revenues
Financial update. The agreement is expected to have no significant impact on IPH’s cash runway in the near future as the product development expenditures until the end of the Phase I trials and the upfront payment to NN are expected to be financed through the early refund (by the French innovation agency Oséo) of the company’s research tax credit receivables (which amounted to 8.9 million euros as at the end of June 2008). The Company estimates that its current balance sheet will be sufficient to finance its pipeline for the next two years. Information meting: The Innate Pharma management team will be hosting an information meeting opened to the press, analysts and investors in the context of the EuroBiO 2008 convention, on October 7, 2008, at 10.30 am CET in the “Palais des Congrès de Paris” (EuroBiO 2008 TV Studio 2, place de la Porte Maillot, 75017 Paris). Investors, journalists and financial analysts may participate in the meeting after a previous registration. Please contact Alize RP (see details in Page 4). Conference call: The information meeting will be broadcasted through a conference call. Please dial +00 (0)0 00 00 00 65. About IPH 2101: IPH 2101 (NN1975) is a fully human anti-KIR monoclonal antibody generated by Novo Nordisk A/S based on a target-profile identified by Innate Pharma and its academic collaborators. The therapeutic principle behind IPH 2101 is based on the activation of NK cells by blocking inhibitory NK cell receptors, thereby potentiating the NK cells anti-cancer activity. This anti-cancer therapeutic approach was indirectly validated by the work of Xxxxxxxxx Xxxxxx Xxxxxxx’s team at the University of Perugia, published in 2002, and recently updated. Pr. Xxxxxxx’x team showed that in bone marrow transplantation for patients suffering from Myeloid Leukemia, grafted NK cells lacking functional KIR (inhibitory) receptors, demonstrated high anti-tumoral activity, resulting in significantly higher survival rate for patients (see more details in Company’s corporate presentation, in the NK platform section). Other transplantation studies were conducted in Multiple Myeloma patients with similar results. IPH 2101 is currently being tested in Phase I clinical trials in acute myeloid leukemia in Europe and multiple myeloma in the United States. The first safety results of these trials are expected in 2009. IPH 2101 was recently elected as one of the top 100 great investigational drugs by the R&D Directions magazine (March 2008 edition). About natural killer...
Financial update. DPW Finance Chief Xxxxxxx Xxxxxx presented the FY 2022-23 Financial Update. The presentation covered Total Operations and Maintenance, Airports Expenditures, and Airports Revenue of all eight County Airports. Xx. Xxxxxx noted that since financial transactions are still accruing for FY 22-23, the numbers showing were not to be considered final numbers. In the Fall, the County and an independent auditor will conduct an audit and post the final numbers on the website for public viewing as the Annual Comprehensive Financial Report. Concluding the Financial Update, Xxxxx Xxxxxx presented FY 2023 though FY 2027-28 Airports Capital Projects. Council requested the following items be presented at the next meeting: • Budget vs Annual • Breakdown of Revenue from Industrial Leases and Aviation Leases • Corrected numbers for FY 25-26 Lease Revenues
